Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of TAVT-45 oral granules versus Zytiga in metastatic castration-sensitive or castration-resistant prostate cancer
2020-005611-46Phase 3Completed
- Sponsor
- Tavanta Therapeutics
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of TAVT-45 in prostate cancer (PCa) (2 arms), sponsored by Tavanta Therapeutics. Primary endpoint: Average serum testosterone on Days 9 and 10. Started Feb 2021; status: completed.
02
Drugs
TAVT-45
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2020-005611-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005611-46.